The reality of prescription drug spending in Medicaid, more than 240 Medicines in Development to treat blood cancers, PPA celebrates its 10th anniversary, look at a patient with rheumatoid arthritis and more
Reality of Prescription Drug Spending in Medicaid – Recent rhetoric on spending in state Medicaid programs often overstates the cost impact of prescription medicines and ignores the competitive biopharmaceutical market that exists in the U.S., which can generate significant savings for Medicaid programs. Read more about spending on medicines in Medicaid here.
More than 240 Medicines in Development – According to a new report from PhRMA and The Leukemia & Lymphoma Society (LLS), biopharmaceutical companies – working alongside nonprofit organizations, academic institutions, government researchers and other partners – currently have more than 240 new medicines in every phase of development to treat blood cancers.
PPA Celebrates 10th Anniversary – This week the Partnership for Prescription Assistance (PPA) celebrated its 10th anniversary of connecting uninsured or underinsured Americans to programs that provide prescription medicines for free or nearly free. In the past decade, the program has connected nearly 9.5 million Americans to public and private assistance programs.
Patient Profile – Learn about the potential out-of-pocket cost burden for a rheumatoid arthritis patient. Be sure to visit the Access Better Coverage website and our Patient Profiles for information on understanding health insurance and getting the information you need to choose the plan that is best for you and your family.
Ask About Adherence – Ask About Adherence is a blog series featuring Q&A’s with experts on medication adherence. In this week’s post, we spoke with Laura Cranston, Pharmacy Quality Alliance (PQA) executive director, on medication synchronization.
Get updates on this subject and/or other relevant issues here.